Thus, anti-HJV-based therapy, which restored hepcidin expression to wild-type levels, completely reverted the obesity-resistant phenotype of matriptase-2 deficient mice. This evidence concerns the gene TMPRSS6 and obesity due to melanocortin 4 receptor deficiency.